Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Versant Capital Management Inc

Versant Capital Management Inc increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1,179.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,130 shares of the company's stock after buying an additional 23,166 shares during the period. Versant Capital Management Inc's holdings in Takeda Pharmaceutical were worth $374,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $52,000. Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical in the 4th quarter worth $61,000. Venturi Wealth Management LLC raised its position in Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after acquiring an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC lifted its holdings in Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.11 during mid-day trading on Wednesday, reaching $15.08. 659,486 shares of the stock traded hands, compared to its average volume of 1,930,494. The stock has a market capitalization of $47.98 billion, a PE ratio of 37.70, a PEG ratio of 0.24 and a beta of 0.26. The business has a 50-day moving average of $14.65 and a 200 day moving average of $14.07. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. On average, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.